1. Home >
  2. M&A >
  3. Growth Capital >
  4. United States >
  5. Colorado >
  6. The BroadOak Fund Invests In KromaTiD

Investment Summary

The BroadOak Fund Invests In KromaTiD

On April 28, 2021, growth capital firm The BroadOak Fund invested in life science company KromaTiD

Investment Highlights
  • This is The BroadOak Fund’s 11th transaction in the Life Science sector.
  • This is The BroadOak Fund’s 12th transaction in the United States.
  • This is The BroadOak Fund’s 1st transaction in Colorado.

Investment Summary
Date 2021-04-28
Target KromaTiD
Sector Life Science
Investor(s) The BroadOak Fund
Deal Type Growth Capital

Target

KromaTiD

Longmont, Colorado, United States
KromaTiD is transforming the fields of genome engineering through the discovery and characterization of genomic structural changes that help leading gene editing and pharmaceutical companies advance therapies to market. KromaTiD offers a powerful suite of products and services for studying genomic rearrangements, custom assay development services and preclinical research support in the Company's research and GLP laboratory operations. KromaTiD's proprietary Pinpoint FISH and directional Genomic Hybridization platforms (dGHTM) have applications throughout genomics, providing direct, definitive data on structural variations that no other technologies can provide. KromaTiD is base din Longmont, Colorado.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 1

Investor

The BroadOak Fund

Investor Investor Investor Investor Investor

Category Growth Capital Firm
Size Small
Type Sector Focused
DESCRIPTION

The BroadOak Fund is the investment affiliate of life science focused investment bank BroadOak Capital Partners. The BroadOak Fund provides growth capital to life sciences tools and service providers that have achieved a level of commercial success. The BroadOak Fund is based in Bethesda, Maryland.

DEAL STATS #
Overall 13 of 26
Sector: Life Science M&A 11 of 21
Type: Growth Capital M&A Deals 5 of 14
State: Colorado M&A 1 of 2
Country: United States M&A 12 of 24
Year: 2021 M&A 2 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-03-16 Genomenon

Ann Arbor, Michigan, United States

Genomenon is an AI-driven genomics company that organizes the world’s genomic knowledge to connect patient DNA to scientific research in the diagnosis and development of treatments for patients with rare genetic diseases and cancer. Genomenon was founded in 2014 and is based in Ann Arbor, Michigan.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-08-16 PBS Biotech

Camarillo, California, United States

PBS Biotech is a manufacturer of single-use bioreactor systems. PBS Bioreactors utilize proprietary “Vertical-WheelTM” technology to support shear sensitive cell therapy products and offer unmatched scale up capabilities. PBS Biotech was founded in 2006 and is based in Camarillo, California.

Buy -
Mergr

Solution for

Product

Company

Legal